1T-LSD
Chemical compound
From Wikipedia, the free encyclopedia
1T-LSD, also known as 1-(thiophene-2-carbonyl)-LSD or as SYN-L-021, is an acylated derivative of lysergic acid diethylamide (LSD), which has been sold as a designer drug.[1][2] It was first identified in Japan in 2023 on blotter paper misrepresented as containing 1D-LSD, but which on analysis was determined to contain 1T-LSD instead.[3] It was also detected in Germany around the same time.[4]
Other names1-(Thiophene-2-carbonyl)-LSD; SYN-L-021
| Clinical data | |
|---|---|
| Other names | 1-(Thiophene-2-carbonyl)-LSD; SYN-L-021 |
| Routes of administration | Oral |
| Drug class | Serotonergic psychedelic; Hallucinogen |
| Identifiers | |
| |
| CAS Number | |
| PubChem CID | |
| ChemSpider | |
| Chemical and physical data | |
| Formula | C25H27N3O2S |
| Molar mass | 433.57 g·mol−1 |
| 3D model (JSmol) | |
| |
Use and effects
Interactions
Chemistry
Society and culture
Legal status
Canada
1T-LSD is not a controlled substance in Canada as of 2025.[5]
United States
1T-LSD is not an explicitly controlled substance in the United States.[6] However, it could be considered a controlled substance under the Federal Analogue Act if intended for human consumption.